0      0

2022 AABB Annual Meeting

AM22-SN06-E - AM22-SN06-E: (On-Demand) AABB/THOR Joint Workshop (Enduring)

Oct 4, 2022 12:00pm ‐ Oct 4, 2022 1:00pm

Credits: None available.


Several recent studies have investigated the role of prehospital transfusions for injured patients with different main findings. This session will introduce the audience to the concept of prehospital transfusions, and describe what happens at the scene of an accident when a transfusion is being considered. Then, the recent THOR-AABB recommendations for prehospital transfusion practice will be discussed, as well as a deep dive into the prehospital transfusion literature (it’s not what meets the eye!). The traditional concerns about transfusing RhD-positive units to trauma patients of unknown RhD type will be described using the most recent literature, and a novel use of low titer group O whole blood as a patient blood management tool will be described.
Agenda: • 8:30-9:00 - What’s It Like to Be a First Responder at an Accident Scene – CJ Winkler, UT Health San Antonio
• 9:00-9:30 - What Does the Latest Evidence Tell Us About Prehospital Transfusion? - Mark Yazer, University of Pittsburgh
• 9:30-10:00 - Roundtable Discussions and Q&A with THOR-AABB Advisory Board Members
• 10:00-10:30 - Review of the THOR-AABB Prehospital Resuscitation Guidelines - Donald Jenkins University of Texas Health Sciences Center, San Antonio
• 10:30-11:00 - How to Assess the Risks and Benefits for New Therapies in Transfusion Medicine– Darrell Triulzi, University of Pittsburgh
• 11:00-11:30 - What are the Risks and Benefits of Transfusing RhD+ RBCs or Low Titer Group O Whole Blood - Nancy Dunbar, Dartmouth-Hitchcock Medical Center
• 11:30-12:00 - Low Titer Group O Whole Blood as Patient Blood Management Tool - Philip Spinella, University of Pittsburgh

Learning Objectives:
  • Recognize what it is like to be a first-responder at the scene of an accident and understand how the decision is made to administer a prehospital transfusion in the field
  • Discuss the THOR-AABB working party recommendations for prehospital transfusion
  • Appraise the latest literature on the efficacy of prehospital transfusions and understand what appropriate outcomes should be measured in future studies
  • Analyze new paradigms in providing blood products to injured patients


  • Dr. Nancy M. Dunbar, MD, Associate Professor for the Dept. of Pathology and Lab Medicine; Associate Medical Director of Transfusion Service and Medical Director of Blood Bank, Dartmouth Health
  • Dr. Donald Jenkins, MD, Department of Surgery, UT Health San Antonio
  • Philip Spinella, MD, Trauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh
  • Darrell Triulzi, MD, Department of Pathology, University of Pittsburgh
  • Cj Winckler, MD, UT Health San Antonio
  • Mark Yazer, MD, Department of Pathology, University of Pittsburgh


  • Alyssa Ziman, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA


  • Alyssa Ziman : BiologyWorks: Stock Shareholder (self-managed) AABB Consulting: Consultant
  • Cj Winckler, MD : Nothing to Disclose
  • Philip Spinella, MD : Secure Transfusion Services: Consultant Cerus: Consultant Haima: Stock Shareholder (self-managed) Haima: Scientific Advisory Board Haima: Scientific Advisory Board Hemanext: Consultant Kalocyte: Stock Shareholder (self-managed)
  • Nancy Dunbar, MD : Verax Biomedical: Medical Advisory Board
  • Mark Yazer, MD : Grifols: Speaker's Bureau Verax: Consultant Hemanext: Speaker's Bureau
  • Donald Jenkins, MD : Nothing to Disclose
  • Darrell Triulzi, MD : Fresenius Kabi: Consultant ReAlta: Consultant


Credits: None available.

You must be logged in and own this session in order to post comments.